Mastercard Opens European Cyber Resilience Centre in Belgium
Mastercard today announced the opening of its European Cyber Resilience Centre (ECRC) at its European Headquarters reaffirming the company’s commitment to combatting cyber threats and enhancing resilience in the region. The new state-of-the-art centre will sharpen defenses against cyber threats, speed up response times and serve as a hub for thought leadership in cybersecurity, fostering collaboration between the public and private sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530937171/en/
Mastercard European Cyber Resilience Centre Opening in Waterloo, Belgium. (From left to right) Michael Miebach, Chief Executive Officer, Mastercard, Mathieu Michel, Belgian State Secretary for Digitalisation, Mark Barnett, President, Mastercard Europe, Catherine De Bolle, Executive Director, Europol. Photo by: Nicolas Peeters. (Photo: Business Wire)
With continuous digitization and unprecedented levels of connectivity, cybercrime presents a shared challenge across all organizations. Fraudsters are using technology in more innovative and sophisticated ways to try and harm consumers and businesses. Cybercrime has turned into a global economy now estimated to be worth trillions of euros.
To address this ever-evolving threat landscape, the ECRC brings together partners from across the public and private sectors. By leveraging its facilities and diverse talent pool, it facilitates collaboration with national cyber intelligence centres, law enforcement agencies, and industry bodies across Europe.
"In today’s hyperconnected world, cybercrime is evolving and so are we. This centre will bring together the brightest minds from business, government and other sectors to stay ahead of threats and make the digital world as secure as possible. Afterall, the work to ensure people can trust that they are safe online doesn’t stop at our four walls — or our firewalls," said Michael Miebach, CEO, Mastercard.
The Centre bolsters Mastercard’s ability to combat cyber threats across the digital ecosystem and helps it protect, detect, and respond to attacks. It fosters deeper connections with customers, partners, and stakeholders and drives collaboration across the region, enhancing resilience.
The Mastercard European Cyber Resilience Centre includes a Fusion Centre, the heart of Mastercard’s organizational incident response, and a Digital Forensics Lab in addition to representatives from more than 20 teams - all crucial to running an effective Resilience Centre.
"At Europol, we are strong believers that no single actor, sector or nation, can face the threats of cybercriminals alone. Each of us has a complementary role to play. By bringing together all relevant actors, the European Cyber Resilience Centre has the potential to bring excellence into our cross-sectoral collaboration," said Catherine De Bolle, Executive Director, Europol.
"It is with great pride that I am here today for the inauguration of the Mastercard European Cyber Resilience Centre. I am delighted that Belgium has been chosen to host this first centre in Europe dedicated to cybersecurity for Mastercard, and even more so because it will be established in the heart of Walloon Brabant. We live in a world where cyber threats are omnipresent and constantly evolving. Cyberattacks know no borders and affect all sectors of our society, from the public to the private sector, from critical infrastructures to ordinary citizens. It is therefore imperative that we unite to meet these challenges with determination and efficiency. This event marks a significant milestone in our shared commitment to strengthening cybersecurity in Europe and Belgium. The European Cyber Resilience Centre represents a key initiative to promote collaboration between the public and private sector, as well as regulatory bodies. By working hand in hand, we can significantly improve our ability to prevent, detect and respond to cyber threats," said Mathieu Michel, Belgian Secretary of State for Digitalization.
The commitment to European security is reflective of Mastercard's role in powering economies and empowering people. This is underscored by its robust infrastructure, which facilitated the protection of 143 billion transactions in 2023 alone. Upholding high standards of privacy, data responsibility, and cybersecurity, Mastercard continues to deliver seamless and secure transactions while safeguarding customer information.
About Mastercard (NYSE: MA), www.mastercard.com
Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530937171/en/
Contact information
James Issokson, james.issokson@mastercard.com, 914-648-9971
Seth Eisen, seth.eisen@mastercard.com, 914-249-3153
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom